Objectives: When study groups fail to publish their results, a subsequent systematic review may come to incorrect conclusions when combining information only from published studies. p53 expression measured by immunohistochemistry is a potential prognostic factor in bladder cancer. Although numerous studies have been conducted, its role is still under debate. The assumption that unpublished studies too harbour evidence on this research topic leads to the question about the attributable effect when adding this information and comparing it with published data. Thus, the aim was to identify published and unpublished studies and to explore their differences potentially affecting the conclusion on its function as a prognostic biomarker. Design...
Context: The biologic potential of prostate cancer (pCA) is variable, and the ability to identify tu...
Approximately 10% of patients with superficial bladder cancer (pTa/pT1) recur with life-threatening ...
Background: Poor reporting compromises the reliability and clinical value of prognostic tumour marke...
Objectives When study groups fail to publish their results, a subsequent systematic review may come...
Despite years of research and hundreds of reports on tumor markers in oncology, the number of marker...
We performed a systematic review of studies that investigated the effect of abnormalities of the tum...
International audienceIntroduction: Mutations in the TP53 gene are indicative of worse outcome in bl...
PURPOSE: The risk of muscle invasive disease in a high risk patient with superficial bladder cancer ...
Despite years of research and hundreds of reports on tumor markers in oncology, the number of marker...
Introduction: The objective of the study was to determine the pattern of p53 expression in patients ...
Introduction: Urinary bladder cancer is one of the common genitourinary malignancy presenting to the...
Contains fulltext : 47399schalken.pdf (publisher's version ) (Closed access)The In...
The number of cancer prognostic markers that have been validated as clinically useful is pitifully s...
This article reviews the literature on some of the available biomarkers such as p53 and its down-str...
The p53 gene status (mutation) and protein alterations (nuclear accumulation detectable by immunohis...
Context: The biologic potential of prostate cancer (pCA) is variable, and the ability to identify tu...
Approximately 10% of patients with superficial bladder cancer (pTa/pT1) recur with life-threatening ...
Background: Poor reporting compromises the reliability and clinical value of prognostic tumour marke...
Objectives When study groups fail to publish their results, a subsequent systematic review may come...
Despite years of research and hundreds of reports on tumor markers in oncology, the number of marker...
We performed a systematic review of studies that investigated the effect of abnormalities of the tum...
International audienceIntroduction: Mutations in the TP53 gene are indicative of worse outcome in bl...
PURPOSE: The risk of muscle invasive disease in a high risk patient with superficial bladder cancer ...
Despite years of research and hundreds of reports on tumor markers in oncology, the number of marker...
Introduction: The objective of the study was to determine the pattern of p53 expression in patients ...
Introduction: Urinary bladder cancer is one of the common genitourinary malignancy presenting to the...
Contains fulltext : 47399schalken.pdf (publisher's version ) (Closed access)The In...
The number of cancer prognostic markers that have been validated as clinically useful is pitifully s...
This article reviews the literature on some of the available biomarkers such as p53 and its down-str...
The p53 gene status (mutation) and protein alterations (nuclear accumulation detectable by immunohis...
Context: The biologic potential of prostate cancer (pCA) is variable, and the ability to identify tu...
Approximately 10% of patients with superficial bladder cancer (pTa/pT1) recur with life-threatening ...
Background: Poor reporting compromises the reliability and clinical value of prognostic tumour marke...